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Summary
 
Dendritic cells (DCs) are bone marrow–derived leukocytes that function as potent antigen pre-
senting cells capable of initiating T cell–dependent responses from quiescent lymphocytes. DC
pulsed with tumor-associated antigen (TAA) peptide or protein have recently been demon-
strated to elicit antigen-specific protective antitumor immunity in a number of murine models.
Transduction of DCs with TAA genes may allow stable, prolonged antigen expression as well
as the potential for presentation of multiple, or unidentified, epitopes in association with major
histocompatibility complex class I and/or class II molecules. To evaluate the potential efficacy
of retrovirally transduced DCs, bone marrow cells harvested from BALB/c mice were trans-
duced with either a model antigen gene encoding 
 
b
 
-galactosidase (
 
b
 
-gal) or a control gene en-
coding rat HER-2/neu (Neu) by coculture with irradiated ecotropic retroviral producer lines.
Bone marrow cells were differentiated into DC in vitro using granulocyte/macrophage col-
ony-stimulating factor and interleukin-4. After 7 d in culture, cells were 45–78% double posi-
tive for DC phenotypic cell surface markers by FACS
 
Ò
 
 analysis, and DC transduced with 
 
b
 
-gal
were 41–72% positive for 
 
b
 
-gal expression by X-gal staining. In addition, coculture of 
 
b
 
-gal
transduced DC with a 
 
b
 
-gal–specific T cell line (CTLx) resulted in the production of large
amounts of interferon-
 
g
 
, demonstrating that transduced DCs could process and present endog-
enously expressed 
 
b
 
-gal. DC transduced with 
 
b
 
-gal and control rat HER-2/neu were then
used to treat 3-d lung metastases in mice bearing an experimental murine tumor CT26.CL25,
expressing the model antigen, 
 
b
 
-gal. Treatment with 
 
b
 
-gal–transduced DC significantly re-
duced the number of pulmonary metastatic nodules compared with treatment with Hank’s bal-
anced salt solution or DCs transduced with rat HER-2/neu. In addition, immunization with
 
b
 
-gal–transduced DCs resulted in the generation of antigen-specific cytotoxic T lymphocytes
(CTLs), which were significantly more reactive against relevant tumor targets than CTLs gen-
erated from mice immunized with DCs pulsed with the L
 
d
 
-restricted 
 
b
 
-gal peptide. The results
observed in this rapidly lethal tumor model suggest that DCs transduced with TAA may be a
useful treatment modality in tumor immunotherapy.
 
D
 
endritic cells (DCs)
 
1
 
 are highly specialized APCs that
possess unique immunostimulatory properties and
function as the principal activators of quiescent T cells, and
thus cellular immune responses in vivo. (1). These bone
marrow–derived leukocytes express a unique repertoire of
cell-surface molecules including high levels of MHC class I
and II, adhesion molecules, and costimulatory molecules,
all of which assist in the activation of T cells. As motile cells
with elaborate cytoplasmic processes and a unique veiled
morphology, DCs are specialized for antigen capture and
transport from the periphery to T cell–dependent areas of
lymphoid organs.
The key role of DCs in the initiation of immune re-
sponses has focused the attention of many investigators on
the potential efficacy of these cells in tumor immunother-
apy. Several groups have demonstrated that DCs pulsed
with peptides from tumor associated antigens (TAA) can
induce antigen-specific antitumor responses in vivo in a va-
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
-gal, 
 
b
 
-galactosidase; 
 
b
 
gP, 
 
b
 
-gal peptide;
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; CM, cytotoxicity medium; DC, dendritic cell;
rm, recombinant murine; TAA, tumor-associated antigen.
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riety of murine tumor models (2–7). The successes of
TAA-pulsed DCs in murine models has supported the use
of autologous, peptide-pulsed DCs in recent clinical trials (8).
In developing strategies to optimize the use of DCs in
tumor immunotherapy, retroviral transduction of DCs
with TAA genes may offer important advantages over pep-
tide-pulsed DCs and other methods of immunization cur-
rently in use. The efficacy of peptide-pulsed DCs might be
limited in vivo, because peptides pulsed onto DCs stay
bound to the MHC molecules only transiently due to vari-
ation in peptide binding affinities, peptide–MHC complex
dissociation, and MHC turnover (9). Additionally, the use
of peptide-pulsed DCs is dependent on the knowledge of
the HLA haplotype of the patient, as well as the restriction
element of the peptide epitopes for any particular antigen.
However, retroviral transduction of DCs with TAA
genes may allow for constitutive expression of the full-
length protein leading to prolonged antigen presentation in
vivo, and presentation of multiple or unidentified antigen
epitopes in the context of MHC class I, and possibly class
II, molecules. Additionally, retrovirally transduced DCs are
entirely autologous, thus abrogating the potential for devel-
opment of neutralizing antibodies with repeated treat-
ments, as can occur with recombinant viral immunization
modalities. TAA-transduced DCs might also be given re-
peatedly and/or combined with other viral or peptide-
based immunization strategies.
As nonreplicating, terminally differentiated cells, mature
DCs are poor candidates for retroviral gene modification.
However, dividing bone marrow progenitor cells can be
efficiently transduced with retroviral vectors (10–12). Be-
cause DCs can successfully be generated in vitro from bone
marrow cells in the presence of GM-CSF–containing cy-
tokine combinations (13–16), we used a method by which
bone marrow cells were retrovirally transduced by cocul-
ture with irradiated producer lines and then differentiated
in vitro to DCs. This method has previously been shown to
be effective in human DC by retroviral transduction of
CD34
 
1
 
 hematopoietic progenitor cells (HPCs) and differen-
tiation of transduced cells in vitro to mature DC (17, 18).
In this study, we demonstrate that murine DCs retrovi-
rally transduced with the gene encoding 
 
b
 
-galactosidase
(
 
b
 
-gal) stably express, process, and present the gene in the
context of MHC class I molecules, and that treatment with
 
b
 
-gal–transduced DCs is capable of mediating effective an-
titumor activity against established pulmonary metastases of
a murine tumor expressing 
 
b
 
-gal.
 
Materials and Methods
 
Cell Lines.
 
CT26.CL25, a subclone of CT26.WT, is a
BALB/c (H-2
 
d
 
) carcinogen-induced, undifferentiated colon car-
cinoma stably transduced with a retrovirus encoding the 
 
lacZ
 
gene driven by the Moloney murine leukemia virus long terminal
repeat (LTR) promoter (19). Tumor cell lines were maintained in
RPMI 1640 supplemented with 10% heat-inactivated fetal calf
serum, 2 mmol/liter glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin (all from Biofluids, Rockville, MD), 1.25 mg/ml
 
amphotericin B (Fungizone; GIBCO BRL, Gaithersburg, MD),
and 50 
 
m
 
g/ml gentamicin sulfate (GIBCO BRL). The CTL line
(CTLx) which recognizes the naturally processed, H-2L
 
d
 
–restricted
 
b
 
-gal epitope p876 to 884, has previously been described (20).
 
Retroviral Transduction and Differentiation of DCs from Bone Mar-
row Cells.
 
CreLacZ and CreNeu are fibroblast-derived, ecotro-
pic-packaging cell lines encoding the 
 
lacZ
 
 and rat 
 
HER-2/neu
 
genes, respectively, in the MFG retroviral vector backbone.
CreLacZ was provided by Richard Mulligan (Children’s Hospi-
tal, Boston, MA) and has previously been described (21). CreNeu
was provided by Elizabeth Jaffee (Johns Hopkins University, Bal-
timore, MD). Bone marrow was flushed from the long bones of
the hind limbs of female 8–12-wk-old BALB/c mice and de-
pleted of erythrocytes with ACK lysing buffer (Biofluids). Bone
marrow cells were depleted of lymphocytes and Ia
 
1
 
 cells by incu-
bation at 4
 
8
 
C in an antibody cocktail (RA3-3A1/6.1, anti–B cell
surface glycoprotein; HO-2.2, anti-Lyt 2.2; B21-2, anti-I-A
 
b,d
 
;
and GK1.5, anti-L3T4 T cell surface antigen; all from American
Type Culture Collection, Rockville, MD) and cytotoxicity me-
dium (CM; Cedarlane Labs. Ltd., Hornby, Canada). Antibody-
bound cells were removed by incubation at 37
 
8
 
C with rabbit
complement (Accurate Chemical and Scientific Corp., Westbury,
NY). Bone marrow cells (7 
 
3
 
 10
 
5
 
 cells/ml) were plated on irradi-
ated (5,000 rads) Cre producer lines (5 
 
3
 
 10
 
3
 
 cells/well) in DC
CM and cocultured for 2 d at 37
 
8
 
C, 5% CO
 
2
 
 in 6-well plates.
Cells were cultured in DC complete medium (DC CM), which is
RPMI-1640 supplemented with 5% heat-inactivated fetal calf se-
rum, 2 mmol/liter glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin, 1.25 
 
m
 
g/ml amphotericin B, 50 
 
m
 
g/ml gentamicin
sulfate, 5 
 
3
 
 10
 
2
 
5
 
 
 
m
 
M 2-mercaptoethanol (2-ME; GIBCO BRL),
20 ng/ml recombinant murine GM-CSF (rmGM-CSF), and 100
ng/ml recombinant murine IL-4 (rmIL-4) (both from Peprotech,
Rocky Hill, NJ). On day 2, nonadherent cells were carefully re-
moved from adherent packaging cell lines and replated at 7 
 
3
 
 10
 
5
 
cells/ml in DC CM. On day 4, 10 ng/ml rmGM-CSF and 50
ng/ml rmIL-4 were added to each well. Cells were harvested on
day 6 by gentle pipetting and replated in 100 mm tissue culture
dishes at 10
 
6
 
 cells/ml with DC CM supplemented with 20 ng/ml
rmGM-CSF and 100 ng/ml rmIL-4.
 
Cell Surface Phenotype.
 
Selected monoclonal antibodies against
the murine molecules (B7-1, B7-2, Ia
 
d
 
, CD11c, B220/CD45R,
CD3, Thy1.2, Mac-1, GR-1, and appropriate isotype controls;
all from PharMingen, San Diego, CA) were obtained directly la-
beled with phycoerythrin or fluorescein isothiocyanate. For phe-
notypic analysis, 10
 
6
 
 day 7 DCs or fresh syngeneic splenocytes
were first incubated with 2.4G2, an antibody directed against the
FcRII
 
g
 
 receptor, and then double stained with the indicated di-
rectly labeled antibodies. Propidium iodide was used to exclude
dead cells from the analysis.
 
Mixed Leukocyte Reaction.
 
The ability of DCs to stimulate
quiescent T cells was assessed by the MLR. Bone marrow–derived
DCs (transduced and nontransduced) or freshly prepared spleno-
cytes were irradiated (2,000 rads) and plated in graded doses with
2 
 
3
 
 10
 
5
 
 allogeneic T cells in 200 
 
m
 
l of RPMI-1640 media sup-
plemented with 10% heat-inactivated fetal calf serum, 2 mmol/li-
ter glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 1
 
3
 
nonessential amino acids, 1 mM sodium pyruvate (all from Bio-
fluids), 1.25 
 
m
 
g/ml amphotericin B (Fungizone; GIBCO BRL),
and 50 
 
m
 
g/ml gentamicin sulfate (GIBCO BRL) (mCM) in flat-
bottomed 96-well tissue culture plates and incubated at 37
 
8
 
C, 5%
CO
 
2
 
 for 3.5 d. Allogeneic T cells were prepared from C57BL/6
mice by passing RBC-depleted splenocytes through an immu-
noaffinity column (R&D Systems, Minneapolis, MN). During 
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the last 6 h of incubation, cultures were pulsed with 1.0 
 
m
 
Ci/well
[
 
3
 
H]thymidine (New England Nuclear, Boston, MA). [
 
3
 
H]thymi-
dine incorporation was measured using a 
 
b
 
 scintillation counter
(Beta Plate; LKB, Gaithersburg, MD).
 
X-Gal Staining.
 
To detect 
 
b
 
-gal expression in transduced
DCs, 5 
 
3
 
 10
 
5
 
 day 7 DCs were washed once with PBS (Biofluids)
and fixed with 1 ml 0.5% glutaraldehyde for 10 min at room tem-
perature. Cells were centrifuged, washed in PBS, and incubated
in 0.5 ml X-gal solution (330 mM K
 
3
 
Fe(CN)
 
6
 
, 330 mM
K
 
4
 
Fe(CN)
 
6
 
, 1 M MgCl
 
2
 
, 10% Triton X-100, 67 mg/ml X-gal,
PBS) for 3–5 h at 37
 
8
 
C, 5% CO
 
2
 
. Bright blue cells in each sample
were counted blindly and expressed as a percentage of the total
cells.
 
In Vitro Cytokine Release Assays.
 
To determine whether endog-
enously expressed 
 
b
 
-gal was processed and presented in the con-
text of MHC class I molecules, 
 
b
 
-gal–specific T cells (CTLx; 10
 
5
 
)
were cultured with day 7 bone marrow–derived DCs or peptide-
pulsed splenocytes (10
 
5
 
) in 200 
 
m
 
l mCM containing 60 IU/ml
IL-2 (Chiron, Emeryville, CA) in flat-bottomed 96-well tissue
culture plates and incubated at 37
 
8
 
C in a 5% CO
 
2
 
 humidified in-
cubator. After 24 h, the supernatant was collected and analyzed
for IFN-
 
g
 
 content with an ELISA assay (R&D Systems).
 
Peptides.
 
The peptide (
 
b
 
gP), TPHPARIGL, representing the
naturally processed H-2 L
 
d
 
-restricted epitope spanning amino ac-
ids 876–884 of 
 
b
 
-gal (22) and the P1A
 
35–43
 
 peptide LPYLG-
WLVF, presented by H-2 L
 
d
 
, were synthesized by Peptide Tech-
nologies (Washington, DC) to a purity .99% as assessed by
HPLC and amino acid analysis.
Antigen Pulsing of DCs. Day 7 bone marrow–derived DC
from BALB/c mice were resuspended in reduced serum media
(Optimem; GIBCO BRL) at 2 3 106 cells/ml and pulsed with
peptide (10 mg/ml) plus human b2-microglobulin (b2m; 10 mg/
ml; Intergen Co., Purchase, NY) for 4 h at room temperature
with gentle mixing. Cells were then washed twice in HBSS
(Biofluids) and DCs (4 3 105) in 0.5 ml HBSS were injected in-
travenously in the tail vein. Freshly isolated syngeneic splenocytes
(5 3 106 cells/ml) were pulsed with peptide in an identical man-
ner as DCs.
In Vivo Treatment Studies. BALB/c mice were challenged
with CT26.CL25 tumor cells (3 3 105) intravenously to establish
pulmonary metastases. On days 3 and 6 after tumor challenge,
mice were treated with day 7 bone marrow–derived transduced
or peptide-pulsed DCs or peptide-pulsed splenocytes intrave-
nously. All mice were randomized before receiving transduced or
peptide-pulsed DCs or splenocytes. Mice were killed on day 12
and metastatic lung nodules were enumerated in a randomized
and blinded manner. Numbers presented are the mean numbers
of pulmonary metastases 6 SEM. The significance of differences
between the groups was determined with the Wilcoxon rank
Sums test. All P values are two-tailed.
In Vitro Antigen Restimulation. For CTL generation, naive
mice were immunized with transduced or peptide-pulsed DCs or
splenocytes (4 3 105 cells) on days 0 and 3. 3–4 wk after the sec-
ond immunization, splenocytes from animals immunized with
transduced or peptide-pulsed DCs or splenocytes were pooled
and restimulated in vitro with the Ld-restricted b-gal peptide for
6 d in EHAA medium (Biofluids) supplemented with 0.5% heat-
inactivated mouse serum (Sigma Chemical Co., St. Louis, MO)
and 5 3 1025 mM 2-mercaptoethanol (2-ME; GIBCO BRL).
On days 2 and 4, 1 ml of fresh media with 60 IU/ml IL-2 (Chi-
ron, Emeryville, CA) was added to each well of cells. On day 7,
restimulated splenocytes were tested for antigen-specific cytolytic
activity and cytokine release. Restimulated splenocytes (105) were
plated in flat-bottomed 96-well tissue culture plates with 105 pep-
tide-pulsed tumor targets in 200 ml media. After 24 h, the super-
natant was collected and analyzed for IFN-g content with an
ELISA assay (R&D Systems).
Cytotoxicity Assays. Target cells (CT26 and CT26.CL25 tu-
mor cells) were harvested and labeled with 200 mCi Na2
51CrO4
(Amersham, Arlington Heights, IL). Restimulated splenocytes
from mice immunized with transduced or peptide-pulsed DCs or
splenocytes were harvested and mixed in graduated doses with 5
3 103 labeled target cells in 150 ml mCM in round-bottomed 96-
well tissue culture plates. Cells were incubated for 4 h at 378C in
a 5% CO2 humidified incubator, the 51Cr released from the target
cells was measured with a g counter (Wallac, Gaithersburg, MD),
and the percent specific lysis was calculated as follows: 100 3
([experimental release 2 spontaneous release]) / ([maximal re-
lease 2 spontaneous release]). Spontaneous and maximal release
were determined in the presence of either medium or 2% SDS,
respectively.
Results
Retroviral Transduction of Bone Marrow Cells and Differentia-
tion into DCs. Bone marrow cells from BALB/c mice
were retrovirally transduced by coculture with the irradi-
ated, ecotropic packaging cell lines, CreLacZ and CreNeu,
for 2 d. This method of gene modification capitalizes on
the suitability of rapidly dividing bone marrow cells as tar-
gets for retroviral transduction (10–12). Transduced bone
marrow cells were then differentiated into DCs in vitro for
an additional 5 d in the presence of rmGM-CSF and rmIL-4.
This method of retroviral transduction consistently generated
a cell population composed of 45–78% DCs as determined
by the percentage of cells double positive for characteristic
DC surface molecules (B7-2, I-Ad, B7-1, CD11c) (Fig. 1).
To determine the percent of cells expressing b-gal in the
transduced cell population, day 7 DCs were X-gal stained.
Transduction efficiencies between 41–72% were consis-
tently observed by this method with very low levels of
background staining in the nontransduced or HER-2/neu–
transduced controls (Table 1). Both transduced and non-
transduced DCs displayed a characteristic DC morphology
with prominent cytoplasmic processes (Fig. 2).
Bone Marrow–derived, Retrovirally Transduced DCs Function
as Potent Stimulators in an Allogeneic Mixed Leukocyte Reaction.
The allostimulatory capacity of the DCs were assessed by
mixed leukocyte reaction (MLR) (Fig. 3). Both transduced
and nontransduced DCs were potent stimulators of quies-
cent, allogeneic T cells in repeated experiments. DCs were
greater than 1,000-fold stronger than fresh, bulk spleno-
cytes in stimulating proliferation of allogeneic T cells. No
significant difference was observed among the nontrans-
duced, b-gal–transduced, or Neu-transduced DCs.
Retrovirally Transduced DCs Process and Present Endogenously
Expressed b-gal. To determine whether the b-gal trans-
duced DCs were capable of processing and presenting b-gal
peptides, transduced and peptide-pulsed DCs were cocul-
tured with an Ld-restricted b-gal–specific T cell line, CTLx
(20). After 24 h, IFN-g was measured in the culture super-
natant (Table 2). DCs transduced with b-gal induced anti-1216 Therapeutic Efficacy of Transduced Dendritic Cells
gen-specific cytokine release from activated T cells indicat-
ing that the endogenously expressed transgene was processed
and presented in an MHC-restricted manner. DCs as well
as fresh, syngeneic splenocytes pulsed with the Ld-restricted
bgP, also induced IFN-g release from CTLx as positive
controls. DC transduced with HER-2/neu or pulsed with
an irrelevant peptide, P1A, failed to cause cytokine release,
demonstrating the antigen specificity of the response.
Retrovirally Transduced DCs Are Therapeutically Effective
against Established Pulmonary Metastases. To determine the
therapeutic efficacy of retrovirally transduced and peptide-
pulsed DCs against established pulmonary metastases,
BALB/c mice were challenged with 3 3 105 CT26.CL25
tumor cells intravenously and treated intravenously with ei-
ther 4 3 105 b-gal or HER-2/neu–transduced DCs, 4 3 105
peptide-pulsed DCs, 4 3 105 bgP-pulsed splenocytes, or
HBSS on days 3 and 6 after tumor challenge. On day 12,
the number of pulmonary metastastic nodules were enu-
merated in a blinded fashion. Mice treated with DCs trans-
duced with b-gal (DC–b-gal) or pulsed with bgP (DC–
bgP) showed a significant reduction in the number of pul-
monary metastases compared with mice treated with
HER-2/neu–transduced (DC–Neu) or P1A peptide-
pulsed DCs (DC–P1A) (Fig. 4 A). The unique role of DCs
in this response is evidenced by the lack of treatment effect
seen in mice treated with bgP-pulsed splenocytes (splen–
bgP). These results are representative of data obtained from
four independent experiments.
To assess further the efficacy of retrovirally transduced
DCs in this tumor model, BALB/c mice bearing
CT26.CL25 pulmonary metastases (3 3 105 tumor cells)
were treated with varying doses of retrovirally transduced
DCs or bgP-pulsed splenocytes (4 3 105–1.6 3 106) on
days 3 and 6 after tumor challenge (Fig. 4 B). Mice receiv-
ing b-gal–transduced DCs showed a significant reduction
in pulmonary metastases compared with mice receiving
HER-2/neu–transduced DCs or bgP-pulsed splenocytes at
all doses tested. Increasing the dose of b-gal–transduced
DCs from 4 3 105 to 1.6 3 106 did not significantly en-
hance therapeutic efficacy. Identical studies with Ld-restricted
bgP-pulsed DCs also failed to show a significant correlation
between antitumor activity and increased DC dose in this
model (data not shown). These studies demonstrate that in
this rapidly lethal tumor model, b-gal–transduced DCs
(DC–b-gal), and bgP-pulsed DCs (DC–bgP) were both
capable of mediating significant, specific antitumor activity.
Figure 1. Cell surface phenotype of bone marrow–derived DCs as de-
termined by FACSÒ analysis. For phenotypic analysis, 106 DCs on day 7
of culture or fresh syngeneic splenocytes were incubated with 2.4G2, an
antibody directed against the FcRIIg receptor, and then double stained
with the indicated directly labeled antibodies. Propidium iodide was used
to exclude dead cells from the analysis. (A) B7-2 and I-Ad with isotype
controls, (B) B7-1 and B7-2 with isotype controls, and (C) CD11c and
B7-2 with isotype controls.
Table 1. Expression of b-gal in Retrovirally Transduced DCs
Percent of cells expressing b-gal
Experiment DC (nontransduced) DC–b-gal DC–Neu
I0 5 4 N D
II 2 72 3
III 1 65 0
IV 4 41 1
V 3 48 0
On day 7 of in vitro culture, DCs were X-gal stained as described in
Materials and Methods. Bright blue cells in each sample were counted
blindly and expressed as a percentage of the total cells.1217 Specht et al.
Generation of b-gal–specific CTLs by In Vivo Immunization
with Bone Marrow–derived DCs. To determine whether anti-
gen-specific CTLs were generated in vivo after DC admin-
istration, naive, nontumor-bearing mice were immunized
on day 0 and day 3 with 4 3 105 peptide-pulsed DCs, 4 3
105 b-gal–transduced DCs, or bgP-pulsed splenocytes in-
travenously. 3–4 wk after the second immunization, sple-
nocytes from immunized mice were restimulated in vitro
with bgP for 6 d. On day 7, restimulated splenocytes were
cocultured with tumor targets, and 24-h IFN-g release was
measured (Table 3).
Splenocytes from mice immunized with either b-gal–
transduced or bgP-pulsed DCs induced antigen-specific
cytokine release; however, the T cells generated in mice
immunized with b-gal–transduced DCs produced signifi-
cantly more IFN-g than T cells from mice immunized
Figure 2. Expression of b-gal as determined by X-gal staining. On day
7 of in vitro culture, nontransduced DCs (A) and b-gal–transduced DCs
(B) were fixed and stained as described in Materials and Methods. Phase
contrast photomicrographs were taken at 1003.
Table 2. Cytokine Release from Ld-restricted, b-gal–specific T Cell 
Line (CTLx) in Response to Bone Marrow–derived DCs
Responder (CTLx)
Stimulator mIFN-g (pg/ml/24 h)
HBSS 73
DC–b-gal transduced 20,890
DC–Neu transduced 169
DC–bgP pulsed 46,140
DC–P1A pulsed 139
Splen–bgP pulsed 68,000
CT26 616
CT25.CL26 113,730
Nontransduced, bone marrow–derived DCs and fresh, syngeneic sple-
nocytes were pulsed with either bgP or P1A plus b2m for 4 h in re-
duced-serum medium. Pulsed cells or transduced DCs (105) were incu-
bated with 105 CTLx for 24 h, and the supernatant was analyzed for
murine IFN-g content. Tumor lines CT26 (parental, wild type) and
CT26.CL25 (which stably expresses b-gal) are included as negative and
positive controls, respectively.
Figure 3. Allogeneic MLR of bone marrow–derived DCs and spleno-
cytes. Bone marrow cells were transduced by coculture with retroviral
producer lines, CreLacZ (DC–b-gal) and CreNeu (DC–Neu), and differ-
entiated into DCs in vitro. DCs were cocultured with allogeneic,
C57BL/6 T cells, isolated from bulk splenocytes by passing cells through
an immunoaffinity column. After 3.5 d in culture, cells were pulsed with
[3H]thymidine as described in Materials and Methods. Results from tripli-
cate wells were corrected for [3H]thymidine incorporation by irradiated
stimulators and T cells alone, and are plotted as the mean 6 SEM.1218 Therapeutic Efficacy of Transduced Dendritic Cells
with bgP-pulsed DCs. Immunization with control DCs or
peptide-pulsed splenocytes failed to generate detectable
CTL activity. These results were observed in three inde-
pendent experiments.
The ability of the CTL to lyse relevant tumor targets was
also assessed (Fig. 5). CTLs grown from mice immunized
with b-gal–transduced DCs demonstrated antigen-specific
lytic activity, whereas CTLs from mice immunized with
bgP-pulsed DCs were minimally reactive. Immunization
with control DCs or bgP-pulsed splenocytes failed to gen-
erate lytic CTLs.
Discussion
The identification of tumor rejection antigens recog-
nized by cytotoxic T cells has led to the development of
vaccination strategies aimed at generating an immune re-
sponse capable of mediating tumor regression in cancer pa-
tients (23). As potent APCs capable of initiating immune
responses from quiescent T cells, DCs pulsed with peptides
from TAA have been successful in murine models in gen-
erating antitumor immunity and treating established tumor
(2–7). Retroviral gene modification of DCs may offer im-
portant advantages over other methods of immunization;
perhaps the most important of these being stable, pro-
longed expression of the full-length antigen leading to pre-
sentation of multiple epitopes in the context of MHC class
I molecules. To examine the potential therapeutic efficacy
of such gene-modified DCs, we used the well-character-
ized murine b-gal tumor model (24, 25).
In generating retrovirally transduced DCs, we took ad-
vantage of the suitability of dividing bone marrow cells as
targets for retroviral gene modification. Gene-modified
cells were then differentiated in vitro to DCs with cytokine
support. This approach for the transduction of DCs has
been used successfully in human CD341 hematopoietic
progenitor cells to generate DCs that stably express the
MART-1 melanoma antigen (17). The data presented here
Figure 4. Active immunotherapy with retrovirally transduced or pep-
tide-pulsed DCs significantly reduces the number of established pulmo-
nary metastases in this 3-d tumor model. (A) 8–10 BALB/c mice/group
were injected intravenously with 3 3 105 CT26.CL25 tumor cells. On
days 3 and 6 after tumor challenge, mice received intravenous injections
of 4 3 105 transduced or peptide-pulsed DCs, fresh peptide-pulsed sple-
nocytes, or HBSS alone. On day 12 after tumor challenge, lungs were
harvested and pulmonary nodules were enumerated in a blinded fashion.
(B) BALB/c mice were challenged with 3 3 105 CT26.CL25 tumor cells.
On days 3 and 6 after tumor challenge, mice received intravenous injec-
tions of transduced DCs or fresh peptide-pulsed splenocytes at varying
doses (4–16 3 105). On day 12 after tumor challenge, lungs were har-
vested and pulmonary nodules were enumerated in a blinded fashion.
Table 3. Cytokine Release From CTL Generated In Vivo by 
Immunization with Bone Marrow–derived DCs
Splenocytes from mice 
immunized with:
Stimulators
mIFN-g (pg/ml/24 h)
CT26/P1A* CT26/bgP‡ CT26.CL25
HBSS 0 0 0
DC–b-gal transduced 266 216,700 151,100
DC–Neu transduced 164 210 372
Splen–bgP pulsed 0 0 0
DC–bgP pulsed 5 1197 1436
DC–P1A pulsed 420 351 477
*CT26 tumor cells pulsed with P1A peptide (10 mg/ml).
‡CT26 tumor cells pulsed with bgP (b-gal Ld peptide) (10 mg/ml).
Splenocytes from animals immunized with transduced or peptide-
pulsed DCs or peptide-pulsed splenocytes were pooled and restimu-
lated in vitro with the Ld-restricted b-gal peptide (bgP) for 6 d in
EHAA media with 30 IU/ml IL-2 (as described in Materials and Meth-
ods). On day 7, restimulated splenocytes (1 3 105) were plated in flat-
bottomed 96-well tissue culture plates with 105 peptide-pulsed tumor
targets. After 24 h, the supernatant was collected and analyzed for IFN-g
content.1219 Specht et al.
provide evidence that primary murine DCs can be stably
gene modified by retroviral transduction to express a model
TAA gene.
The ability of the transduced DCs to process and present
endogenously expressed b-gal was evidenced by recogni-
tion and specific cytokine release by b-gal–specific T cells.
The difference observed in IFN-g release in response to
b-gal–transduced DCs and bgP-pulsed DCs is attributable
to the high concentration of peptide pulsed onto the DCs
compared with the transduced DCs, where the antigen is pro-
cessed and presented at physiologic levels. A similar effect is
also observed with the peptide-pulsed splenocytes in this assay.
Although we saw no difference in specific antitumor ac-
tivity between b-gal–transduced and b-gal peptide-pulsed
DCs under the conditions tested, it is possible that further
titrations of DCs and tumor dose might reveal a difference
in antitumor response between these two treatments. In
fact, immunization with b-gal–transduced DCs generated
CTLs that were significantly more reactive in vitro than CTLs
grown from mice immunized with b-gal peptide-pulsed
DCs. The expression and presentation of multiple epitopes in
the b-gal–transduced DCs might lead to the generation of
CTLs with multiple specificities. The presence of such ad-
ditional CTL populations in the restimulated T cells might
have contributed to the enhanced reactivity observed in
cytolytic activity. In addition, the difference in CTL reactiv-
ity may be due to the prolonged presentation of b-gal in
vivo by b-gal–transduced DCs compared with peptide-
pulsed DCs. An increased duration of antigen presentation
could lead to the generation of a greater number of CTLs,
the expansion of which may require a longer period of
time than the rapidly lethal, 12-d pulmonary metastases
model will allow. We are currently attempting development
of longer tumor models to determine whether transduced
DCs might have enhanced in vivo activity compared with
peptide-pulsed DCs.
Our current and future efforts are focused on the devel-
opment of tumor models that more closely approximate
the characteristics of the immune response to tumor in pa-
tients. The cloning and characterization of several shared,
human, melanoma-associated antigens that are recognized
by T cells, including tyrosinase, tyrosinase-related protein-1
(TRP-1), MART-1, and gp100, provide opportunities for
studying the ability of retrovirally transduced DCs to in-
duce an immune response against nonmutated, self-anti-
gens (26–29). In the mouse, TRP-2 has recently been
identified as a nonmutated, melanoma-associated antigen in
B16 melanoma (30). We have begun construction of retro-
viral vectors encoding the murine melanoma-associated an-
tigens, TRP-2 and gp100, expressed in B16 melanoma.
The ability of transduced DCs to immunize against and/or
treat this nonimmunogenic tumor may be a useful predic-
tor of the potential efficacy of retrovirally transduced DCs
in humans.
Approaches designed to enhance the immunostimulatory
function of DCs are also being explored. These include
transduction of DCs with cytokine genes in an attempt to
enhance DC immunogenicity. Activation of DCs by
CD40–CD40 ligand association, as well as the use of adju-
vant cytokines such as GM-CSF and IL-12, in vivo are also
being investigated.
The ability to transduce a primary DC retrovirally to ex-
press stably a foreign gene also introduces a novel, poten-
tially powerful, approach to studying the mechanisms of
DC activation and differentiation as well as protein traffick-
ing and antigen processing in primary DCs. Retroviral
transduction of genes encoding proteins containing intra-
cellular targeting sequences, such as the hexapeptide present in
melanosomal membrane proteins gp75 and gp100 (31),
might allow efficient trafficking of protein antigens to the
MHC class II endosomal pathway, resulting in presentation
of antigen epitopes in the context of MHC class I and II
molecules. The efficient presentation of antigen in associa-
tion with both class I and class II may allow the initiation of
a more potent immune response.
In summary, we present here evidence that murine DCs
can be retrovirally transduced to express stably a model
TAA gene. TAA-transduced DCs generated by this
method express the transgene at high levels, and are capable
of processing and presenting the antigen in the context of
MHC class I molecules. Immunization with gene-modified
DCs results in the production of highly reactive, antigen-
specific CTLs. Finally, treatment with TAA-transduced
DCs is capable of mediating effective antitumor activity
against established pulmonary metastases. These results sug-
gest that TAA-transduced DCs may be a promising treat-
ment modality in tumor immunotherapy.
Figure 5. Lysis of tumor targets by CTLs from mice immunized with
transduced (DC–b-gal and DC–Neu) or peptide-pulsed DCs (DC–bgP
and DC–P1A) or peptide-pulsed splenocytes (splen–bgP). Splenocytes
from immunized animals were harvested, restimulated in vitro for 7 d
with the Ld-restricted b-gal peptide876–884, and mixed in graduated doses
with 5 3 103 51Cr-labeled target cells. Cells were incubated for 4 h at
378C in a 5% CO2 humidified incubator. 51Cr released from the lysed tar-
get cells was measured. Results are plotted as the mean percent specific ly-
sis 6 SEM.1220 Therapeutic Efficacy of Transduced Dendritic Cells
References
1. Steinman, R.M. 1991. The dendritic cell system and its role
in immunogenicity. Annu. Rev. Immunol. 9:271–296.
2. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C.
Celluzzi, L.D. Falo, C.J. Melief, S.T. Ildstad, W.M. Kast,
A.B. DeLeo, and M.T. Lotze. 1995. Bone marrow–derived
dendritic cells pulsed with synthetic tumor peptides elicit
protective and therapeutic antitumor immunity. Nat. Med. 1:
1297–1302.
3. Celluzzi, C.M., J.I. Mayordomo, W.J. Storkus, M.T. Lotze,
and L.D. Falo. 1996. Peptide-pulsed dendritic cells induce
antigen-specific CTL-mediated protective tumor immunity.
J. Exp. Med. 183:283–287.
4. Paglia, P., C. Chiodoni, M. Rodolfo, and M.P. Colombo.
1996. Murine dendritic cells loaded in vitro with soluble pro-
tein prime cytotoxic T lymphocytes against tumor antigen in
vivo. J. Exp. Med. 183:317–322.
5. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo,
M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy
of murine tumors with tumor peptide-pulsed dendritic cells:
dependence on T cells, B7 costimulation, and T helper cell.
J. Exp. Med. 183:87–97.
6. Mayordomo, J.I., D.J. Loftus, H. Sakamoto, C.M. De Ce-
sare, P.M. Appasamy, M.T. Lotze, W.J. Storkus, E. Appella,
and A.B. DeLeo. 1996. Therapy of murine tumors with p53
wild-type and mutant sequence peptide-based vaccines. J.
Exp. Med. 183:1357–1365.
7. Pogador, A., D. Snyder, and E. Gilboa. 1996. Induction of
antitumor immunity using bone marrow–generated dendritic
cells. J. Immunol. 156:2918–2926.
8. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski,
B. Taidi, E.g., Engleman, and R. Levy. 1996. Vaccination of
patients with B-cell lymphoma using autologous antigen-
pulsed dendritic cells. Nat. Med. 2:52–58.
9. Germain, R.N., and D.H. Margulies. 1993. The biochemis-
try and cell biology of antigen processing and presentation.
Annu. Rev. Immunol. 11:403–450.
10. Dunbar, C.E., N.E. Seidel, S. Doren, S. Sellers, A.P. Cline,
M.E. Metzger, B.A. Agricola, R.E. Donahue, and D.M. Bo-
dine. 1996. Improved retroviral gene transfer into murine
and Rhesus peripheral blood or bone marrow repopulating
cells primed in vivo with stem cell factor and granulocyte
colony–stimulating factor. Proc. Natl. Acad. Sci. USA. 21:
11871–11876.
11. Nienhuis, A.W. 1994. Gene transfer into hematopoietic stem
cells. Blood Cells. 20:141–148.
12. Cassel, A., M. Cottler-Fox, S. Doren, and C.E. Dunbar.
1993. Retroviral-mediated gene transfer into CD 34-enriched
human peripheral blood stem cells. Exp. Hematol. 21:585–591.
13. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S.
Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Genera-
tion of large numbers of dendritic cells from mouse bone
marrow cultures supplemented with granulocyte/macrophage
colony-stimulating factor. J. Exp. Med. 176:1693–1702.
14. Witmer-Pack, M.D., W. Olivier, J. Valinsky, G. Schuler, and
R.M. Steinman. 1987. Granulocyte/macrophage colony-
stimulating factor is essential for the viability and function of
cultured murine epidermal Langerhans cells. J. Exp. Med.
166:1484–1498.
15. Inaba, K., R.M. Steinman, M. Witmer-Pack, K. Aya, M. In-
aba, T. Sudo, S. Wolpe, and G. Schuler. 1992. Identification
of proliferating dendritic cell precursors in mouse blood. J.
Exp. Med. 175:1157–1167.
16. Caux, C., C. Dezutter-Dambuyant, D. Schmitt, and J.
Banchereau. 1992. GM-CSF and TNF-alpha cooperate in
the generation of dendritic Langerhans cells. Nature (Lond.).
360:258–261.
17. Reeves, M.E., R.E. Royal, J.S. Lam, S.A. Rosenberg, and P.
Hwu. 1996. Retroviral transduction of human dendritic cells
with a tumor-associated antigen gene. Cancer Res. 56:5672–
5677.
18. Henderson, R.A., M.T. Nimgaonkar, S.C. Watkins, P.D.
Robbins, E.D. Ball, and O.J. Finn. 1996. Human dendritic
cells genetically engineered to express high levels of the hu-
man epithelial tumor antigen mucin (MUC-1). Cancer Res.
56:3763–3770.
19. Wang, M., V. Bronte, P.W. Chen, L. Gritz, D. Panicali, S.A.
Rosenberg, and N.P. Restifo. 1995. Active immunotherapy
of cancer with a nonreplicating recombinant fowlpox virus
encoding a model tumor-associated antigen. J. Immunol. 154:
4685–4692.
20. Wang, M., P.W. Chen, V. Bronte, S.A. Rosenberg, and
N.P. Restifo. 1995. Anti-tumor activity of cytotoxic T lym-
phocytes elicited with recombinant and synthetic forms of a
model tumor-associated antigen. J. Immunother. Emphasis Tu-
mor Immunol. 18:139–146.
21. Danos, O., and R.C. Mulligan. 1988. Safe and efficient gen-
eration of recombinant retroviruses with amphotropic and
ecotropic host ranges. Proc. Natl. Acad. Sci. USA. 85:6460–
6464.
22. Gavin, M.A., M.J. Gilbert, S.R. Riddell, P.D. Greenberg,
and M.J. Bevan. 1995. Alkali hydrolysis of recombinant proteins
allows for the rapid identification of class I MHC-restricted
CTL epitopes. J. Immunol. 151:3971–3980.
23. Rosenberg, S.A. 1995. The development of new cancer ther-
apies based on the molecular identification of cancer regres-
sion antigens. Cancer J. Sci. Am. 1:90–100.
24. Bronte, V., K. Tsung, J.B. Rao, P.W. Chen, M. Wang, S.A.
Rosenberg, and N.P. Restifo. 1995. IL-2 enhances the func-
tion of recombinant poxvirus–based vaccines in the treatment
of established pulmonary metastases. J. Immunol. 154:5282–
The authors thank A. Mixon and E. Fitzgerald for assistance in FACSÒ analyses, and P. Spiess and D. Jones
for their assistance with animal experiments.
Address correspondence to Patrick Hwu, Surgery Branch, National Cancer Institute, National Institutes of
Health, Bldg. 10, Rm 2B42, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-402-1156; FAX: 301-
435-5167; E-mail: pat@helix.nih.gov
Received for publication 4 June 1997 and in revised form 16 July 1997.1221 Specht et al.
5292.
25. Irvine, K.R., J.B. Rao, S.A. Rosenberg, and N.P. Restifo.
1996. Cytokine enhancement of DNA immunization leads to
effective treatment of established pulmonary metastases. J. Im-
munol. 156:238–245.
26. Robbins, P.F., M. El-Gamil, Y. Kawakami, E. Stevens, J.R.
Yannelli, and S.A. Rosenberg. 1994. Recognition of tyrosi-
nase by tumor-infiltrating lymphocytes from a patient re-
sponding to immunotherapy (erratum published 54:3952).
Cancer Res. 54:3124–3126.
27. Wang, R.F., P.F. Robbins, Y. Kawakami, X.Q. Kang, and
S.A. Rosenberg. 1995. Identification of a gene encoding a
melanoma tumor antigen recognized by HLA-A3–restricted
tumor–infiltrating lymphocytes (erratum published 181:
1261).  J. Exp. Med. 181:799–804.
28. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L.
Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994.
Cloning of the gene coding for a shared human melanoma
antigen recognized by autologous T cells infiltrating into tu-
mor. Proc. Natl. Acad. Sci. USA. 91:3515–3519.
29. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K.
Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki,
and S.A. Rosenberg. 1994. Identification of a human mela-
noma antigen recognized by tumor-infiltrating lymphocytes
associated with in vivo tumor rejection. Proc. Natl. Acad. Sci.
USA. 91:6458–6452.
30. Bloom, M.B., D. Perry-Lalley, P.F. Robbins, Y. Li, M. El-
Gamil, S.A. Rosenberg, and J.C. Yang. 1997. Identification
of tyrosinase-related protein 2 as a tumor rejection antigen
for the B16 melanoma. J. Exp. Med. 185:453–459.
31. Vijayasaradhi, S., B. Bouchard, and A.N. Houghton. 1995.
Intracellular sorting and targeting of melansomal membrane
proteins: identification of signals for sorting of the human
brown locus protein, gp75. J. Cell Biol. 130:807–820.